ALLO vs ENTX: stock comparison and AI forecast
Allogene Therapeutics, Inc. (ALLO) and Entera Bio Ltd. (ENTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ALLO Allogene Therapeutics, Inc.
- Market Cap
- $359M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ENTX Entera Bio Ltd.
- Market Cap
- $518M
- P/E Ratio
- 9.1x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ENTX is 1.4 times larger than ALLO by market capitalization ($518M against $359M).
- ENTX carries 1.68 times debt per unit of equity, against 0.30 times for ALLO.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ALLO | ENTX |
|---|---|---|
| Market Cap | $359M | $518M |
| P/E Ratio | – | 9.06x |
| P/B Ratio | 0.92x | 71.25x |
| EPS | $-0.83 | $0.33 |
| Book Value/Share | $1.14 | $0.04 |
| Revenue/Share | – | $0.00 |
| FCF/Share | $-0.31 | $-0.06 |
Profitability & Margins
| Metric | ALLO | ENTX |
|---|---|---|
| ROE | -44.4% | – |
| ROA | -34.1% | – |
| ROIC | -40.2% | -82.9% |
| Operating Margin | -4099.3% | – |
| Net Margin | -3760.0% | – |
| EBT Margin | -3702.2% | – |
Financial Health
| Metric | ALLO | ENTX |
|---|---|---|
| Current Ratio | 7.79x | 8.98x |
| D/E Ratio | 0.30x | 1.68x |
| Financial Leverage | 1.30x | 2.68x |
| Interest Coverage | -6.6x | – |
| Working Capital | $261M | $17M |
Cash Flow
| Metric | ALLO | ENTX |
|---|---|---|
| Operating Cash Flow | -$109M | -$11M |
| Free Cash Flow | -$109M | -$11M |
| Capital Spending | -$180K | -$70K |
Operational Efficiency
| Metric | ALLO | ENTX |
|---|---|---|
| Asset Turnover | – | 0.00x |
| Fixed Assets Turnover | – | 0.0x |
Income Statement
| Metric | ALLO | ENTX |
|---|---|---|
| Total Revenue | – | $0.00M |
| Operating Income | -$190M | -$14M |
| Net Income | -$174M | – |
| R&D Expense | $133M | $9M |
| SG&A Expense | – | $550K |
| Cost of Goods Sold | – | $0.00M |
Dividend & Shareholder Information
| Metric | ALLO | ENTX |
|---|---|---|
| Shares Outstanding | 345M | 173M |
| EPS Growth | – | 32.0% |
ALLO vs ENTX: stock comparison and AI forecast
Which is bigger, ALLO or ENTX?
ENTX is 1.4 times larger than ALLO by market capitalization ($518M against $359M).
Which one does Intratio's AI model rank higher, ALLO or ENTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.